Unlocking Orphan GPCRs with an Innovative Forward Trafficking Approach
Application of GPCR Pharmacotrafficking & Cell-Based Assays Orphan G Protein-Coupled Receptors (oGPCRs) comprise one-third of the druggable GPCR space1. Despite their pharmacotherapeutic... Read More
ACCELERATING CYTOKINE DRUG DISCOVERY AND QC LOT RELEASE TESTING WITH QUALIFIED, FUNCTIONAL CELL-BASED ASSAYS
Cytokines and their receptors have emerged as major drug targets for inflammatory and autoimmune diseases, allergies, and, more recently, in cancer immunotherapies... Read More
USE OF AUTOMATED FUNCTIONAL, CELL-BASED BIOASSAYS
Importance in Drug Discovery & Development for Quality Testing Programs Cell-based assays have emerged as crucial tools for basic and applied research.... Read More
BioMAP Toxicity Signature Analysis Around the Globe: Responding to Our International Team
Our Eurofins Discovery team in Japan presented at the 2021 Japanese Safety Pharmacology Society Annual Meeting, where they had the opportunity to... Read More
Rapidly Identify Therapeutics that Modulate Protein Levels Induced by Protein Degraders such as PROTACs
As newer, cutting-edge therapeutic technologies emerge, an increasing need for rapid and reliable screening tools follows. Recent advances in the field of... Read More
Uses & Advantages of Membrane Preparations for GPCRs
Cellular membrane proteins play important functions in many biological processes. Understanding their roles often requires that these proteins be isolated from their... Read More
Enabling High-Throughput Screening for Cellular Compound-Target Engagement through InCELL Pulse™
Information on compound-target engagement obtained from traditional in vitro binding assays differs greatly from that in a physiologically relevant model (in vivo).... Read More
Comparison of InCELL Hunter™ vs InCELL Pulse™ for Analyzing Compound-Target Engagement
Whether you’re looking to screen a library of drug candidates for binding to a particular target protein, checking drug cell membrane penetration,... Read More
Eliminating Donor Variability in ADCC Assays –Implementation in QC Lot Release
Challenges of ADCC Assay Development Class I therapeutic antibodies achieve their clinical efficacy by binding to their target antigen and through Fragment... Read More
ACCELERATING BIOLOGICS DEVELOPMENT PROGRAMS WITH PHASE-APPROPRIATE READY-TO-USE POTENCY BIOASSAYS
Progressing Biotherapeutics to Clinic Faster Biological activity of a biotherapeutic is a Critical Quality Attribute (CQA), which needs to be accurately measured... Read More